Podcast: Play in new window | Download (Duration: 39:50 — 36.5MB)
Subscribe: Spotify | iHeartRadio | Email | Deezer | RSS | More
Join us in Miami Beach in March for StartUp Health @ ViVE 2022: startuphealth.com/vive
Nightingale Health, a Finnish company that StartUp Health backed in 2016, uses a new kind of blood testing to predict future disease risk so that people can change the course of their health before it’s too late. They’ve designed a way to analyze blood samples that pulls 250 times more data from that sample than a typical test. They use artificial intelligence and machine learning to correlate that data with future disease risk, like diabetes and heart disease. Then they put the result in simple terms so that patients can see trends and take action.
This year, Nightingale took three big strides forward. They went public on the Finnish Nasdaq, which gave them capital to scale globally. They rolled out at-home testing kits so more people can benefit from Nightingale’s disease prediction. And they acquired a genomics company that will allow them to bake genetic information into their app and provide people with even more personalized health assessments.
We sat down with Nightingale CEO and Co-founder Teemu Suna to hear more about their blood testing technology and how it could change preventative health globally by getting patients to see their potential future and then change the course of their health.
Join us in Miami Beach in March at StartUp Health @ ViVE 2022 to meet Health Transformers: startuphealth.com/vive
—
Learn more and connect with the team at Nightingale.
Investors: How to invest in StartUp Health Moonshots healthmoonshots.com
Want more content like this? You can subscribe to the podcast as well as other health innovation updates at startuphealth.com/content.
Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.